Ponvory for the treatment of adults with relapsing forms of multiple sclerosis with active disease - Approved in European Union
The European Commission ( EC ) has approved Ponvory ( Ponesimod ) for the treatment of adult patients with relapsing multiple sclerosis ( RMS ) with active disease defined by clinical or imaging features.
The EC approval of Ponvory is based on data from the phase 3 OPTIMUM trial, a multicentre, randomised, double-blind, parallel-group, active-controlled superiority study of 1,133 adult patients ( aged 18-55 years ) in 28 countries.
The trial was designed to evaluate the efficacy and safety of once daily oral Ponesimod ( 20mg ) versus once-daily Teriflunomide ( 14mg ), an approved and widely-used first-line oral treatment, in adult patients with relapsing multiple sclerosis.
The large, phase 3 study has shown superior efficacy of Ponesimod 20mg on the primary endpoint, annualised relapse rate ( ARR ), with a rate reduction of 30.5% ( p less than 0.001 ) compared with Teriflunomide.
Ponesimod has also shown statistically significant superiority on one of the secondary endpoints, combined unique active lesions ( CUALs ).
Ponesimod has significantly reduced the number of new inflammatory lesions on brain MRI by 56% ( p less than 0.0001 ) at week 108 when compared to Teriflunomide.
Within the OPTIMUM study, overall, the number of treatment-emergent adverse events reported was similar between the Ponesimod and Teriflunomide treated groups, and the majority were mild / moderate and did not warrant treatment discontinuation.
The most commonly reported adverse events in either the Ponesimod 20mg group versus the Teriflunomide 14mg group were alanine aminotransferase ( ALT ) enzyme elevations ( 19.5% vs 9.4% ), nasopharyngitis ( 19.3% vs 16.8% ), headache ( 11.5% vs 12.7% ), upper respiratory tract infection ( 10.6% vs 10.4% ) and alopecia ( 3.2% vs 12.7% ).
The safety profile of Ponesimod is consistent with the known safety profile of other S1P receptor modulators, although a head-to-head comparison, other than with Teriflunomide, is not available.
Ponesimod is an oral, highly selective S1P1 modulator that functionally inhibits S1P1 receptor activity and, in doing so, it is believed to reduce the number of circulating lymphocytes.
In patients with multiple sclerosis, inflammatory immune cells, including lymphocytes, can cross the blood brain barrier into the brain and damage myelin, the protective sheath that insulates nerve cells. Damage to myelin slows or halts nerve conduction, producing the neurologic signs and symptoms of multiple sclerosis.
Multiple sclerosis is a chronic autoimmune inflammatory disease of the central nervous system ( CNS ). Symptoms vary by person, but common symptoms include fatigue, balance and walking problems, numbness or tingling, dizziness and vertigo, vision problems, bladder and bowel problems and weakness. ( Xagena )
Source: Janssen, 2021
Keytruda as first-line treatment in adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer, approved by European Commission
The European Commission has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, as a monotherapy for the first-line treatment of...
Keytruda plus Lenvima combination for patients with certain types of advanced endometrial carcinoma - FDA approved
The U.S. Food and Drug Administration ( FDA ) has approved the combination of Keytruda ( Pembrolizumab ), an anti-PD-1...
Opdivo + Yervoy as the first immunotherapy treatment for previously untreated unresectable malignant pleural mesothelioma, FDA approved
The U.S. Food and Drug Administration ( FDA ) has approved Opdivo ( Nivolumab ) 360 mg every three weeks...
Kesimpta, self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis, FDA approved
The FDA ( US Food and Drug Administration ) has approved Kesimpta ( Ofatumumab, formerly OMB157 ) as an injection...
Patients with autoimmune disease and lung cancer pose a multidisciplinary treatment challenge, particularly with the advent of immunotherapy. However, the...
Newborns face unique immunological challenges immediately after birth. As they depart a relatively sterile fetal environment, they are abruptly exposed...
Keytruda for patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, as monotherapy...
In December 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, a city of 11 million...
Opdivo plus Yervoy for patients with hepatocellular carcinoma previously treated with Sorafenib, FDA approved
Opdivo ( Nivolumab ) 1 mg/kg plus Yervoy ( Ipilimumab ) 3 mg/kg ( injections for intravenous use ) was...